PDF(Pubmed)
Abstract：
Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with a survival rate of approximately 12-18 months. Glioblastoma is highly heterogeneous, demonstrating that different types of cells from the same tumor can manifest distinct gene expression patterns and biological behaviors. Conventional therapies such as temozolomide, radiation, and surgery have limitations. As of now, there is no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted therapies to PI3K, NFKβ, JAK-STAT, CK2, WNT, NOTCH, Hedgehog, and TGFβ pathways. The highly novel application of oncolytic viruses and nanomaterials in combating glioblastoma are also discussed. Despite scores of clinical trials for glioblastoma, the prognosis remains poor. Progress in breaching the blood-brain barrier with nanomaterials and novel avenues for targeted and combination treatments hold promise for the future development of efficacious glioblastoma therapies.
摘要：
胶质母细胞瘤是最常见的原发性脑肿瘤，也是恶性程度最高的脑肿瘤，生存率约为12-18个月。胶质母细胞瘤是高度异质性的，表明来自同一肿瘤的不同类型的细胞可以表现出不同的基因表达模式和生物学行为。常规疗法如替莫唑胺，辐射,手术也有局限性。截至目前,胶质母细胞瘤没有治愈方法.本综述讨论了根除胶质母细胞瘤的替代治疗方法。包括PI3K的靶向治疗，NFKβ,JAK-STAT,CK2,WNT,NOTCH,刺猬,和TGFβ途径。还讨论了溶瘤病毒和纳米材料在对抗胶质母细胞瘤中的高度新颖的应用。尽管胶质母细胞瘤的临床试验得分，预后仍然很差。纳米材料突破血脑屏障的进展以及靶向和联合治疗的新途径为有效的胶质母细胞瘤治疗的未来发展带来了希望。
